Recombinant constructs of Borrelia burgdorferi
AssigneeThe Research Foundation of State University of New York
InventorsRaymond J. Dattwyler, Maria J. C. Gomes-Solecki, Benjamin J. Luft, John J. Dunn
Life of this patent
Estimating the term…
Abstract
Novel chimeric nucleic acids, encoding chimeric Borrelia proteins comprising OspC or an antigenic fragment thereof and OspA or an antigenic fragment thereof, are disclosed. Chimeric proteins encoded by the nucleic acid sequences are also disclosed. The chimeric proteins are useful as vaccine immunogens against Lyme borreliosis, as well as for immunodiagnostic reagents.
Claims21
A chimeric protein comprising a first and a second polypeptide, wherein the first polypeptide comprises OspC from Borrelia burgdorferi sensu lato and wherein the second polypeptide comprises OspA from Borrelia burgdorferi sensu lato, such that the OspC polypeptide is linked to the N-terminus of the OspA polypeptide.
A chimeric protein comprising an amino acid sequence selected from the group consisting of:
- SEQ ID NOs:
- 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178 and 180.
A physiological composition to vaccinate against and treat Borrelia infection in animals or humans, the composition comprising;
- a) a chimeric protein comprising at least a first and a second polypeptide, wherein the first polypeptide comprises Borrelia burgdorferi sensu lato OspC and wherein the second polypeptide comprises Borrelia burgdorferi sensu lato OspA, such that OspC is linked to the N-terminus of OspA, the amount being effective to ellicit an immune response to Borrelia burgdorferi;
- b) a physiologically-acceptable carrier or vehicle;
- and
- c) an adjuvant.
Dependencies are inferred from the claim text.